Efficacy, Tolerability, and Safety of DFN-15

Trial Profile

Efficacy, Tolerability, and Safety of DFN-15

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Feb 2018

At a glance

  • Drugs Celecoxib (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors Dr Reddys Laboratories
  • Most Recent Events

    • 30 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 May 2018.
    • 20 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top